Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?

Desmet CJ, Peeper DS.

Cell Mol Life Sci. 2006 Apr;63(7-8):755-9. Review.

PMID:
16568244
[PubMed - indexed for MEDLINE]
2.

The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective.

Geiger TR, Peeper DS.

Cancer Res. 2005 Aug 15;65(16):7033-6. Review.

PMID:
16103047
[PubMed - indexed for MEDLINE]
Free Article
3.

TrkB as a therapeutic target for ovarian cancer.

Siu MK, Wong OG, Cheung AN.

Expert Opin Ther Targets. 2009 Oct;13(10):1169-78. doi: 10.1517/14728220903196787. Review.

PMID:
19694498
[PubMed - indexed for MEDLINE]
4.

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Toschi L, Jänne PA.

Clin Cancer Res. 2008 Oct 1;14(19):5941-6. doi: 10.1158/1078-0432.CCR-08-0071. Review.

PMID:
18829470
[PubMed - indexed for MEDLINE]
Free Article
5.

Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.

Pillai A.

Neurosignals. 2008;16(2-3):183-93. doi: 10.1159/000111562. Epub 2008 Feb 5. Review.

PMID:
18253057
[PubMed - indexed for MEDLINE]
6.

On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Thiele CJ, Li Z, McKee AE.

Clin Cancer Res. 2009 Oct 1;15(19):5962-7. doi: 10.1158/1078-0432.CCR-08-0651. Epub 2009 Sep 15. Review.

PMID:
19755385
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Targeting TrkB neurotrophin receptor to treat depression.

Rantamäki T, Castrén E.

Expert Opin Ther Targets. 2008 Jun;12(6):705-15. doi: 10.1517/14728222.12.6.705 . Review.

PMID:
18479217
[PubMed - indexed for MEDLINE]
8.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
[PubMed - indexed for MEDLINE]
9.

Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies.

Kozisek ME, Middlemas D, Bylund DB.

Pharmacol Ther. 2008 Jan;117(1):30-51. Epub 2007 Aug 15. Review.

PMID:
17949819
[PubMed - indexed for MEDLINE]
10.

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Tortora G, Ciardiello F, Gasparini G.

Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Epub 2008 Jul 1. Review.

PMID:
18594498
[PubMed - indexed for MEDLINE]
11.
12.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
[PubMed - indexed for MEDLINE]
13.

Src inhibitors in breast cancer therapy.

Hiscox S, Nicholson RI.

Expert Opin Ther Targets. 2008 Jun;12(6):757-67. doi: 10.1517/14728222.12.6.757 . Review.

PMID:
18479222
[PubMed - indexed for MEDLINE]
14.

Targeting the c-MET signaling pathway for cancer therapy.

Liu X, Yao W, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2008 Jul;17(7):997-1011. doi: 10.1517/13543784.17.7.997 . Review.

PMID:
18549337
[PubMed - indexed for MEDLINE]
15.

Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.

Bjelogrlić SK, Srdić T, Radulović S.

J BUON. 2006 Jul-Sep;11(3):267-76. Review.

PMID:
17309148
[PubMed - indexed for MEDLINE]
16.

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Review.

PMID:
18718806
[PubMed - indexed for MEDLINE]
17.

Targeting ion channels in cancer: a novel frontier in antineoplastic therapy.

Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A.

Curr Med Chem. 2009;16(1):66-93. Review.

PMID:
19149563
[PubMed - indexed for MEDLINE]
18.

Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?

Lupu R, Menendez JA.

Curr Pharm Biotechnol. 2006 Dec;7(6):483-93. Review.

PMID:
17168665
[PubMed - indexed for MEDLINE]
19.

Preclinical and clinical development of novel agents that target the protein kinase C family.

Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E.

Semin Oncol. 2006 Aug;33(4):466-78. Review.

PMID:
16890801
[PubMed - indexed for MEDLINE]
20.

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Tabernero J.

Mol Cancer Res. 2007 Mar;5(3):203-20. Review.

PMID:
17374728
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk